Enterprise Value
241.8M
Cash
408.9M
Avg Qtr Burn
-53.11M
Short % of Float
37.98%
Insider Ownership
1.51%
Institutional Own.
-
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
FT576 (iNK hnCD16) + daratumumab Details Cancer, Multiple myeloma | Phase 1 Data readout | |
FT500 (PD1/PD-L1) Details Solid tumor/s, Cancer | Phase 1 Data readout | |
FT819 (CAR-19, TCR-KO) Details Solid tumor/s, Cancer, B-cell lymphoma | Phase 1 Data readout | |
FT522 (CAR NK Cell Program) Details Cancer, B-cell lymphoma | Phase 1 Initiation | |
FT516 (NK cells - engineered CD16 FcR) Details Solid tumor/s, B-cell lymphoma, Diffuse large B cell lymphoma | Failed Discontinued | |
FT596 (CAR19, hnCD16, IL-15RF) + rituximab Details B-cell lymphoma, B-cell malignancies, Chronic lymphocytic leukemia | Failed Discontinued | |
FT596 (CAR19, hnCD16, IL-15RF) + R-CHOP Details B-cell lymphoma, B-cell malignancies, Chronic lymphocytic leukemia | Failed Discontinued | |
FT538 (hnCD16 + IL-15RF + CD38KO) Details Multiple myeloma, Cancer | Failed Discontinued | |
FT516 (NK cells - engineered CD16 FcR) + rituximab Details Solid tumor/s, B-cell lymphoma, Cancer | Failed Discontinued | |
ProTmune (CD34+) Details Acute graft-versus host disease | Failed Discontinued |